Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Dec 24, 2022 4:00pm

239 Views

Post# 35191231

RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

One oF the key indicators of a chat board " basher".

Since they cant attack the science or the issues, they distract by attacking those who post the factual issues.

Factual:

1.Onc has on- going collaborations with Merck, Pfizer, Roche, & Incyte.
2. they have an in-place partnership with China partner AN...BTW, not far away from $$$ milestones payments to Onc.
3. The recent pancreatic results ( trial with Roche Tecentriq), showed results 3x standard of care & enabled a very quick Fast Track designation.
4. Onc is now positioned to establish 2 phase three , partnerships.
There are more things I could go on about, but enough for now.
any doubt, visit the ony web site, under investor presentations.